Charles Haaser - Yield10 Bioscience Chief Accounting Officer, Vice President - Finance
| YTENDelisted Stock | USD 1.90 0.04 2.06% |
President
Mr. Charles B. Haaser is a Chief Accounting Officer, Vice President Finance of the Company. Mr. Haaser became the Company Chief Accounting Officer effective November 3, 2014, after serving as the Companys Corporationrationrate Controller since 2008. Mr. Haaser has more than thirty years of experience in accounting and finance, primarily working for publicly traded U.S. companies. Before joining Metabolix, Mr. Haaser was the Corporationrationrate Controller of Indevus Pharmaceuticals, Inc. from 2006 to 2008. He was the Corporationrationrate Controller and Principal Accounting Officer at ABIOMED, Inc. from 1998 to 2006 and additionally served as ABIOMEDs Acting Chief Financial Officer from 2003 to 2006. From 1997 to 1998 Mr. Haaser was controller for Technical Communications Corporation and from 1986 to 1997 was the Director of Finance at ISI Systems, Inc. From 1984 to 1986 Mr. Haaser was an auditor in the commercial audit division of Price Waterhouse LLP . Mr. Haaser received a bachelors degree in business administration from the University of Notre Dame, an MBA from Northeastern University and a Masters of Science in Taxation from Bentley University. Mr. Haaser became a Certified Public Accountant in 1997. since 2016.
| Age | 68 |
| Tenure | 8 years |
| Phone | 617 583 1700 |
| Web | https://www.yield10bio.com |
Yield10 Bioscience Management Efficiency
The company has return on total asset (ROA) of (1.5028) % which means that it has lost $1.5028 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.0809) %, meaning that it created substantial loss on money invested by shareholders. Yield10 Bioscience's management efficiency ratios could be used to measure how well Yield10 Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Yield10 Bioscience currently holds 3.18 M in liabilities with Debt to Equity (D/E) ratio of 0.28, which may suggest the company is not taking enough advantage from borrowing. Yield10 Bioscience has a current ratio of 6.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Yield10 Bioscience's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Joseph Podwika | Nutrien | 56 | |
| Douglas Barnard | CF Industries Holdings | 65 | |
| Hao Yu | China Green Agriculture | 59 | |
| Pedro Farah | Nutrien | N/A | |
| Christopher Bohn | CF Industries Holdings | 56 | |
| Denise Stump | Scotts Miracle Gro | 70 | |
| Marcelo Pessanha | Lavoro Limited Class | 40 | |
| Sam Eathington | Corteva | 52 | |
| Michael Webb | Nutrien | N/A | |
| Walter Precourt | The Mosaic | 55 | |
| David Johnson | American Vanguard | 67 | |
| Andrew Sandifer | FMC Corporation | 54 | |
| Corrine Ricard | The Mosaic | 61 | |
| Anantha Desikan | ICL Israel Chemicals | 53 | |
| Miri Mishor | ICL Israel Chemicals | 60 | |
| Anthony Hendrix | American Vanguard | 53 | |
| Diane Allemang | FMC Corporation | 64 | |
| Steven Douglas | Nutrien | N/A | |
| E Stone | Intrepid Potash | 58 | |
| David Anderson | Corteva | 71 | |
| Robert Gilbane | American Vanguard | 73 | |
Management Performance
| Return On Equity | -15.08 | ||||
| Return On Asset | -1.5 |
Yield10 Bioscience Leadership Team
Elected by the shareholders, the Yield10 Bioscience's board of directors comprises two types of representatives: Yield10 Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Yield10. The board's role is to monitor Yield10 Bioscience's management team and ensure that shareholders' interests are well served. Yield10 Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Yield10 Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lynne Brum, Vice President - Planning and Communications | ||
| Nicholas Renegar, Director Operations | ||
| Kristi Snell, Chief Science Officer, Vice President - Research | ||
| Charles Haaser, Chief Accounting Officer, Vice President - Finance | ||
| ScD Sinskey, CoFounder Director | ||
| Oliver Peoples, President CEO, Director |
Yield10 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Yield10 Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -15.08 | ||||
| Return On Asset | -1.5 | ||||
| Operating Margin | (240.28) % | ||||
| Current Valuation | 3.96 M | ||||
| Shares Outstanding | 642.54 K | ||||
| Shares Owned By Insiders | 12.59 % | ||||
| Shares Owned By Institutions | 11.79 % | ||||
| Number Of Shares Shorted | 60.7 K | ||||
| Price To Earning | (3.19) X | ||||
| Price To Book | 11.23 X |
Pair Trading with Yield10 Bioscience
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Yield10 Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Yield10 Bioscience will appreciate offsetting losses from the drop in the long position's value.Moving against Yield10 Stock
| 0.83 | IPI | Intrepid Potash | PairCorr |
| 0.79 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.78 | IE | Ivanhoe Electric | PairCorr |
| 0.72 | MHGVY | Mowi ASA ADR | PairCorr |
| 0.66 | CTVA | Corteva | PairCorr |
The ability to find closely correlated positions to Yield10 Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Yield10 Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Yield10 Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Yield10 Bioscience to buy it.
The correlation of Yield10 Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Yield10 Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Yield10 Bioscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Yield10 Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Yield10 Stock
If you are still planning to invest in Yield10 Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Yield10 Bioscience's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |